Specialty biopharmaceutical company Santarus has announced the commercial launch of ulcerative colitis therapy, Uceris (budesonide) extended release tablets. Uceris that contains a locally acting glucocorticosteroid, budesonide, in a ...
Tags: Santarus, Uceris, ulcerative colitis therapy
Santarus has obtained FDA approval for ulcerative colitis therapy, Uceris (budesonide) extended release tablets. A 9mg dose tablet is approved for administration once a day in adult patients with ulcerative colitis for up to eight weeks. ...